Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
IASLC WCLC 2026
2026 ASCO GI
ASCO Breakthrough 2026
ASCO 2026
ESTRO 2026
Calendar
View All
Topics
AI in Oncology
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
No results found for survivorshi
Suggestions:
Ensure words are spelled correctly.
Try rephrasing keywords or using synonyms.
Try less specific keywords.
«
1
»
Advertisement
Advertisement
Sep
16
Today In Oncology
Two Phase III Trials Explore B7-H3–Directed ADCs in Relapsed SCLC
PD-L1–High Metastatic NSCLC: First-Line Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet PFS Endpoint
Ivonescimab Significantly Improves Overall Survival vs Pembrolizumab in PD-L1–Positive Advanced NSCLC
Izalontamab Brenitecan Active in Previously Treated EGFR NSCLC
DAROL Examines Darolutamide With Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer
View More
Advertisement
